Shelton Capital Management Buys 1,329 Shares of DexCom, Inc. (NASDAQ:DXCM)

Shelton Capital Management raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 4.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,177 shares of the medical device company’s stock after purchasing an additional 1,329 shares during the period. Shelton Capital Management’s holdings in DexCom were worth $4,392,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Cary Street Partners Investment Advisory LLC boosted its holdings in DexCom by 40.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 1,038 shares of the medical device company’s stock valued at $133,000 after purchasing an additional 300 shares during the period. Artisan Partners Limited Partnership raised its stake in shares of DexCom by 22.0% in the 2nd quarter. Artisan Partners Limited Partnership now owns 2,426,385 shares of the medical device company’s stock valued at $311,815,000 after buying an additional 436,852 shares in the last quarter. Private Advisor Group LLC raised its stake in shares of DexCom by 126.3% in the 2nd quarter. Private Advisor Group LLC now owns 19,034 shares of the medical device company’s stock valued at $2,446,000 after buying an additional 10,622 shares in the last quarter. Cetera Advisors LLC raised its stake in shares of DexCom by 2.3% in the 2nd quarter. Cetera Advisors LLC now owns 6,030 shares of the medical device company’s stock valued at $775,000 after buying an additional 135 shares in the last quarter. Finally, Cetera Advisor Networks LLC raised its stake in shares of DexCom by 4.2% in the 2nd quarter. Cetera Advisor Networks LLC now owns 29,495 shares of the medical device company’s stock valued at $3,790,000 after buying an additional 1,180 shares in the last quarter. 93.88% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Steven R. Altman sold 1,000 shares of the firm’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $77.58, for a total value of $77,580.00. Following the transaction, the director now owns 60,700 shares of the company’s stock, valued at approximately $4,709,106. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Steven R. Altman sold 1,000 shares of DexCom stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $77.58, for a total transaction of $77,580.00. Following the transaction, the director now owns 60,700 shares of the company’s stock, valued at approximately $4,709,106. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Barry J. Regan sold 2,019 shares of DexCom stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $95.22, for a total transaction of $192,249.18. Following the transaction, the executive vice president now directly owns 64,250 shares in the company, valued at approximately $6,117,885. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,752 shares of company stock valued at $850,297. 0.41% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DXCM. SVB Leerink began coverage on shares of DexCom in a research note on Monday, October 16th. They issued an “outperform” rating and a $110.00 price objective for the company. TheStreet cut shares of DexCom from a “b-” rating to a “c+” rating in a research note on Wednesday, September 6th. Leerink Partnrs restated an “outperform” rating on shares of DexCom in a research note on Monday, October 16th. Piper Sandler increased their target price on shares of DexCom from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Friday, July 28th. Finally, Robert W. Baird dropped their target price on shares of DexCom from $153.00 to $130.00 and set an “outperform” rating for the company in a research report on Monday, August 21st. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $130.93.

DexCom Stock Up 0.2 %

Shares of NASDAQ:DXCM opened at $104.97 on Friday. The firm has a market cap of $40.56 billion, a P/E ratio of 115.35, a P/E/G ratio of 2.13 and a beta of 1.13. The company has a quick ratio of 2.50, a current ratio of 2.80 and a debt-to-equity ratio of 1.07. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $139.55. The company’s 50-day moving average price is $91.03 and its two-hundred day moving average price is $109.88.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 26th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.16. The company had revenue of $975.00 million for the quarter, compared to analyst estimates of $939.64 million. DexCom had a net margin of 11.08% and a return on equity of 25.05%. The company’s revenue for the quarter was up 26.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.28 EPS. As a group, research analysts forecast that DexCom, Inc. will post 1.43 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.